Abstract: Isolated, recombinant nucleic acids which encode an isoleucyl-tRNA synthetase (IleRS) of human origin have been used to make expression constructs and transformed host cells for the production of a recombinant human IleRS. A recombinant enzyme has been purified, and is active in the specific aminoacylation of tRNA by isoleucine. Isolated, recombinant enzyme, and antibodies made specifically thereto, can be useful in assays to diagnose and monitor the autoimmune disease known as "antisynthetase syndrome." The essential isoleucyl-tRNA synthetases of microbes pathogenic in humans can be the targets of inhibitory agents having antimicrobial activity. A human isoleucyl-tRNA synthetase, isolated and purified, can be used to assess the toxic effect in humans of such an inhibitory agent in various biochemical activity assays. This human enzyme can also be expressed in "tester strains," whose cells rely upon the function of the human isoleucyl-tRNA synthetase for tRNA.sup.Ile charging.
Type:
Grant
Filed:
June 6, 1995
Date of Patent:
June 2, 1998
Assignees:
Cubist Pharmaceuticals, Inc., Cancer Institute, Japanese Foundation for Cancer Research
Inventors:
Kiyotaka Shiba, Janice E. Kranz, Paul R. Schimmel
Abstract: Isolated, recombinant nucleic acids which encode alanyl-tRNA synthetase (AlaRS) of human origin have been used to make expression constructs and transformed host cells for the production of recombinant human AlaRS. The recombinant enzyme has been purified, and is active in the specific aminoacylation of tRNA by alanine. The isolated, recombinant human AlaRS is also recognized by antibodies made by patients with the particular autoimmune disease known as "antisynthetase syndrome" in which the patients produce antibodies against the human alanyl-tRNA synthetase in their own cells. Thus, the isolated, recombinant enzyme, and antibodies made specifically thereto, can be useful in assays to diagnose and monitor this disease. The essential alanyl-tRNA synthetases of microbes pathogenic in humans can be the targets of inhibitory agents having antimicrobial activity.
Type:
Grant
Filed:
April 21, 1995
Date of Patent:
May 13, 1997
Assignees:
Cubist Pharmaceuticals, Inc., Cancer Institute, Japanese Foundation for Cancer Research, Massachusetts Institute of Technology
Inventors:
Kiyotaka Shiba, Paul R. Schimmel, Tracy L. Ripmaster
Abstract: 5-((3,4-dimethoxyphenetyl)methylamino)- 2-(3,4-dimethoxy-phenyl)-2-isopropylvaleronitrile or a pharmaceutically acceptable salt thereof is effective to prevent metastasis of cancer.
Type:
Grant
Filed:
January 16, 1987
Date of Patent:
November 29, 1988
Assignees:
Cancer Institute, Japanese Foundation for Cancer Research, Eisai Co., Ltd.
Abstract: A human gene termed APC is disclosed. Methods and kits are provided for assessing mutations of the APC gene in human tissues and body samples. APC mutations are found in familial adenomatous polyposis patients as well as in sporadic colorectal cancer patients. APC is expressed in most normal tissues. These results suggest that APC is a tumor suppressor.
Type:
Grant
Filed:
October 24, 2001
Date of Patent:
October 27, 2009
Assignees:
The Johns Hopkins University, Astrazeneca United Kingdom, Ltd., Cancer Institute, Japanese, Foundation for Cancer Research, The University of Utah
Inventors:
Bert Vogelstein, Kenneth W. Kinzler, Hans Albertsen, Rakesh Anand, Mary Carlson, Joanna Groden, Philip Hedge, Geoff Joslyn, Alexander Fred Markham, Yusuke Nakumura, Andrew Thliveris, Raymond White